Lopinavir with Ritonavir Reduces the HIV RNA Level in Cerebrospinal Fluid
Open Access
- 1 December 2007
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 45 (11) , 1511-1517
- https://doi.org/10.1086/523002
Abstract
Background. Combination antiretroviral (ARV) therapy can reduce human immunodeficiency virus (HIV) RNA levels in cerebrospinal fluid (CSF) and plasma and improve immunocompetence. However, HIV-associated neurocognitive disorders persist, possibly because some ARV drugs do not reach therapeutic concentrations in the brain. The primary objective of this study was to determine whether lopinavir plus ritonavir (LPV-rtv) used alone reduced the HIV RNA level in CSF. Methods. The study was an open-label, 24-week trial of sequential ARV therapy. Fifteen subjects were enrolled and received LPV-rtv therapy. Ten subjects reached the primary study end point at week 3, before at least 2 other ARV drugs were added to the treatment regimen. CSF and blood samples were obtained before treatment and after 3, 12, and 24 weeks of treatment. Results. LPV-rtv therapy alone reduced the HIV RNA level in CSF in all subjects (median change in HIV RNA level, -1.42 log10 copies/mL), including 5 who had slower decreases in HIV RNA level in CSF than in plasma—an indicator of autonomous central nervous system infection. Among 9 subjects who completed 12 weeks of LPV-rtv—containing therapy, the HIV RNA level was below quantitation in the CSF samples from 8 subjects and in the plasma samples from 6 subjects. By week 24, HIV RNA levels were below quantitation in samples of both fluids from all 8 subjects. Conclusions. LPV-rtv therapy alone for 3 weeks consistently reduces the HIV RNA level in CSF by at least 10-fold in most individuals, including those likely to have autonomous HIV replication in the central nervous system. Because it penetrates the central nervous system in therapeutic concentrations and appears to reduce HIV replication in the central nervous system, LPV-rtv may benefit subjects who receive a diagnosis of or are at risk for HIV-associated neurocognitive disorders.Keywords
This publication has 20 references indexed in Scilit:
- Treatment Benefit on Cerebrospinal Fluid HIV‐1 Levels in the Setting of Systemic Virological Suppression and FailureThe Journal of Infectious Diseases, 2006
- Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disordersAnnals of Neurology, 2004
- The impact of HIV-associated neuropsychological impairment on everyday functioningJournal of the International Neuropsychological Society, 2004
- Predictive Validity of Global Deficit Scores in Detecting Neuropsychological Impairment in HIV InfectionJournal of Clinical and Experimental Neuropsychology, 2004
- Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patientsAIDS, 2004
- Initial Validation of a Screening Battery for the Detection of HIV-Associated Cognitive ImpairmentThe Clinical Neuropsychologist, 2004
- Human Immunodeficiency Virus–1 RNA Levels in Cerebrospinal Fluid Exhibit a Set Point in Clinically Stable Patients Not Receiving Antiretroviral TherapyThe Journal of Infectious Diseases, 2003
- Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: Clinical correlationsHIV Research & Clinical Practice, 2002
- Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrierJournal of Clinical Investigation, 2000
- Hopkins Verbal Learning Test – Revised: Normative Data and Analysis of Inter-Form and Test-Retest ReliabilityThe Clinical Neuropsychologist, 1998